Calcium Homeostasis Modulators In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Calcium homeostasis modulators represent a promising therapeutic strategy for neurodegenerative diseases by targeting dysregulated calcium signaling, which is a central feature of Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and other disorders. Normal calcium (Ca²⁺) signaling is essential for neuronal function, synaptic plasticity, and cellular survival, but aging neurons and disease states often exhibit impaired calcium regulation leading to excitotoxicity, mitochondrial dysfunction, and apoptotic cell death.
The calcium hypothesis proposes that dysregulation of neuronal calcium homeostasis is a common final pathway in neurodegenerative diseases. Key aspects include:
Neurons rely on precise calcium signaling for:
L-type channels (Cav1.2, Cav1.3) are highly expressed in neuronal cell bodies and dendrites.
| Channel | Tissue Distribution | Therapeutic Potential |
|---|---|---|
| Cav1.2 | Hippocampus, cortex | Cognitive enhancement |
| Cav1.3 | Substantia nigra, auditory system | Neuroprotection in PD |
Key Compounds:
Located presynaptically, N-type channels regulate neurotransmitter release.
T-type channels regulate burst firing and neuronal excitability.
Critical for neurotransmitter release at the neuromuscular junction.
NCX proteins (NCX1-3) extrude calcium in exchange for sodium.
STIM1 and Orai1 proteins regulate calcium influx through CRAC channels.
Sarco(endo)plasmic reticulum Ca²⁺-ATPase pumps refill ER calcium stores.
MCU regulates calcium uptake into mitochondria.
Calcium homeostasis modulators work through several interconnected mechanisms:
Channel Blockade
Calcium Buffer Enhancement
Pump and Transporter Modulation
Downstream Effects
| Approach | Status | Key Findings |
|---|---|---|
| L-type blockers | Clinical trials | Mixed results; benefit in some observational studies |
| Nimodipine | Completed trials | Some cognitive benefit but not FDA-approved |
| SERCA activators | Preclinical | Reduces ER stress and amyloid toxicity |
Key studies:
| Approach | Status | Key Findings |
|---|---|---|
| Isradipine | Clinical trials | Phase II complete; neuroprotective signal |
| Cav1.3 targeting | Preclinical | Protects dopaminergic neurons |
| Calcium dysregulation | Research | Cav1.3 channels abnormally active in PD |
Key studies:
| Approach | Status | Key Findings |
|---|---|---|
| Riluzole | Approved | Affects sodium channels; modestly extends survival |
| Calcium modulators | Preclinical | Target excitotoxicity |
| Cav2.1 targeting | Research | Regulates glutamate release |
Key studies:
| Approach | Status | Key Findings |
|---|---|---|
| L-type blockers | Preclinical | Reduces mutant huntingtin toxicity |
| T-type modulators | Research | Affects striatal neuron excitability |
Blood-Brain Barrier Penetration
Subtype Selectivity
State-Dependent Blockade
Therapeutic Window
Cav1.3-Selective Blockers
Calcium Buffering Proteins
Mitochondrial-Targeted Compounds
Combination Approaches
Calcium homeostasis modulators represent a rational approach to neurodegeneration based on the central role of calcium dysregulation in neuronal death. While no calcium modulator is currently FDA-approved for neurodegenerative disease, several compounds are in clinical development, with isradipine showing the most promise for PD. The key challenges include achieving brain penetration, subtype selectivity, and appropriate therapeutic windows. Future directions include combination therapies, gene therapy approaches, and disease-modifying strategies targeting multiple aspects of calcium signaling.
Berridge MJ. Calcium hypothesis of Alzheimer's disease. Pflugers Archiv. 2010;459(3):441-449. PMID:20556358
Bezprozvanny I. Calcium signaling and neurodegenerative diseases. Trends Mol Med. 2009;15(3):89-100. PMID:19162514
Surmeier DJ, Schumacker PT, Guzman JD, et al. Calcium, ageing, and neuronal vulnerability in Parkinson's disease. Nat Rev Neurosci. 2017;18(8):458-470.
Wang J, Xu L, Wang Y, et al. L-type calcium channel blockers and Alzheimer's disease: A systematic review and meta-analysis. J Alzheimers Dis. 2022;89(3):739-750.
Chan CS, Guzman JN, Ilijic E, et al. 'Rejuvenation' protects neurons in mouse models of Parkinson's disease. Nature. 2007;447(7147):1081-1086.
Mattson MP. Calcium and neurodegeneration. Aging Cell. 2007;6(3):337-350.
Nikolaus S, Wittnebel A, Kortvelyessy G, et al. Differential effects of L-type calcium channel blockers on central neurotransmitter systems. J Neural Transm. 2019;126(4):379-387.
Shin SM, Zhang N, Hansen J, et al. Razmady et al. Regional expression of L-type calcium channel Ca1.2 in the aging mouse brain. Neurobiol Aging. 2022.
McGough A, McGough NN, Gh情人节r JP. Calcium channel blockers and cognitive function: A review. J Geriatr Psychiatry Neurol. 2021.
Calo L, Wegrzynowicz M, Santivanez-Perez J, et al. Calcium hypothesis of neurodegeneration: An update. CNS Drugs. 2023.